US/UK/Canada

Share

Pick a time period -
Tags ( Active)

UNION therapeutics announces publication of biomarker modulation profile of orismilast using novel approach with tape-stripping and Olink technology

Hellerup, Denmark, October 31, 2025 – UNION therapeutics A/S (“UNION”), a privately held, clinical stage, pharmaceutical development company focused on immunology, announces publication of a paper documenting the ability of orismilast, a potent selective PDE4 B/D inhibitor, to modulate key disease driving cytokines measured via a pioneering combination of extensive tape-stripping and Olink® technology from the IASOS study in psoriasis published in Experimental Dermatology.1)   The paper, authored by the IASOS principal investigator and co-investigators, reports the first data to date

UNION therapeutics Announces Participation in Upcoming Investor Conferences

Hellerup, Denmark, March 27, 2025 – UNION therapeutics A/S (UNION), a privately-held, clinical stage, pharmaceutical development company focused on immunology, today announced that management will participate in the following upcoming investor conferences: · H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, where management will participate in virtual one-on-one meetings as well as present at 10am ET. · Canaccord Genuity’s 2nd I&I Disease Symposium on May 8, 2025, where management will participate in the company panel.

UNION therapeutics announces presentation of preliminary data from Phase 2a investigator-initiated study with orismilast in ulcerative colitis at the 20th ECCO Congress

· Poster presentation of preliminary data from the Phase 2a investigator-initiated study UCORIS in ulcerative colitis (UC) at the 20th ECCO Congress · UC is a chronic inflammatory bowel disease that causes inflammation and ulcers (sores) in the lower digestive tract with limited efficacious treatment options available · Orismilast is a high-potency PDE4B/D inhibitor with broad anti-inflammatory properties in development for oral treatment of inflammatory diseases, including hidradenitis suppurative (HS)   Hellerup, Denmark, February 21, 2025 – UNION therapeutics A/S (UNION), a

UNION therapeutics announces full-year results for 2024

Hellerup, Denmark, February 12, 2025, – UNION therapeutics A/S (“UNION”), a privately held, clinical stage, pharmaceutical development company focused on immunology, announces full-year results for the period January 1 to December 31, 2024.  During 2024 we saw the promising results of orismilast in an additional indication, this time atopic dermatitis (AD), with another dataset indicating potency superior to previous generations of PDE4-inhibitors while retaining the well-established safety profile of the compound class, supporting the broad potential of orismilast.   The promise

UNION therapeutics to present at the Dermatology Summit 2025, opening the week of the 43rd Annual J.P. Morgan Health Care Conference

Hellerup, Denmark, January 10, 2025 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that CEO Dr. Kim Kjøller will present at the Dermatology Summit, January 12th 2025 at the Hyatt Regency San Francisco.   Dr. Kjøller will be presenting at 3.15 pm (PST), Sunday January 12, 2025, and will provide an update on orismilast and its potential across immunology as a safe oral treatment amidst injectable biologics. The presentation will include recent data from Phase 2 studies of orismilast in atopic

UNION therapeutics to present at the 7th Annual Evercore Healthcare Conference

Hellerup, Denmark, December 4, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CEO of UNION will present at the 7th Annual Evercore ISI HealthCONx Conference taking place on December 3-5, 2024 at The Loews Coral Gables Hotel in Coral Gables, Florida.   Dr. Kjøller will be presenting at 09:10am EST on Thursday, December 5, 2024, and will provide an update on orismilast and its potential across immunology as a safe oral treatment amidst injectable biologics. The

UNION therapeutics to present at the 8th Annual Dermatology Drug Development Summit in Boston

Hellerup, Denmark, November 7, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CO-CEO of UNION will present at the seminar on Clinical and Commercial Strategy at the 8th Annual Dermatology Drug Development Summit on 12-14 November 2024, in Boston, US.   Dr. Kjøller will discuss recent trials in atopic dermatitis (AD) and the ability between outcome scales to adequately differentiate between placebo and active treatment, particularly in the segment of patients with

UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment

· Orismilast Phase 2b results in atopic dermatitis (AD) presented today as a late-breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) Congress 2024 · Orismilast demonstrated clear treatment effect with statistical significance for all dose arms on the registrational endpoint of IGA0/1 at week 16 · Orismilast also demonstrated fast onset of itch reduction as measured by ≥4 point reduction in NRS at week 2 with statistical significance for all dose arms · Biomarkers including TARC (CCL17) improved statistically significantly for all orismilast

UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024

· ADESOS Phase 2b results with orismilast in atopic dermatitis (AD) selected as late-breaking oral presentation · Additionally, two posters on data from the pioneering use of tape stripping for biomarker analysis in the ADESOS study and additional ADESOS Phase 2b results · Orismilast is a next generation, high potency PDE4 B/D selective inhibitor with reported positive results from a Phase 2b study in psoriasis and Phase 2, IIT, study in hidradenitis suppurativa (HS); orismilast is currently being evaluated in an ongoing Phase 2, IIT study in ulcerative colitis (UC) · UNION plan to

UNION therapeutics appoints drug development leader Dr. Peter Kristensen to its Board of Directors

· Dr. Peter Kristensen, MD, DMSc, EMBA, appointed new member of UNION’s Board of Directors, bringing more than 25 years of expertise from drug development and regulatory approval from pharmaceutical companies · Strengthening of the Board of Directors with late-stage drug development expertise follows read-out of three Phase 2/2b studies with orismilast and prior to initiation of Phase 3 studies with orismilast in atopic dermatitis (AD)   Hellerup, Denmark, August 6, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused

UNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024

· ADESOS Phase 2b study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe atopic dermatitis (AD) has successfully completed · Results from the ADESOS study have been selected for an oral presentation at the late breaking research sessions at the RAVE Conference 2024 · Orismilast is a next generation, high potency PDE4 B/D selective inhibitor with reported positive results from a Phase 2b study in psoriasis and Phase 2 study in hidradenitis suppurativa (HS); orismilast is currently being evaluated in an ongoing IIT study in ulcerative colitis (UC) ·

UNION therapeutics announces publication of results from the OSIRIS Phase 2 study of orismilast in hidradenitis suppurativa in the Journal of the European Academy of Dermatology and Venereology

· Orismilast demonstrated clinically relevant improvements in patients with hidradenitis suppurativa (HS), confirming the relevance of orismilast for the treatment of HS · 67% of patients completing 16 weeks of treatment achieved HiSCR50, and the mean reduction in AN-count in patients completing treatment with orismilast was 33.1% · A 48.2% reduction in skin-related pain, which is one of the most bothersome symptoms for HS patients, was observed for the patients completing treatment · Positive topline results have been reported with orismilast in psoriasis and is currently being

UNION therapeutics announces full-year results for 2023

Hellerup, Denmark, February 7, 2024, – UNION therapeutics A/S (“UNION”), a privately held, clinical stage, pharmaceutical development company focused on immunology, announces full-year results for the period January 1 to December 31, 2023. 2023 has been a year of great progress for UNION with positive read-outs from two clinical studies with lead candidate orismilast, a next-generation, high potency PDE4B/D inhibitor, in psoriasis and hidradenitis suppurativa (HS). Results have been presented at leading scientific conferences and published in peer-reviewed journals. Additionally, patient

UNION therapeutics to present at the 42nd Annual J.P. Morgan Healthcare Conference

Hellerup, Denmark, January 5, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CEO of UNION will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8-11, 2024, in San Francisco, US.  Dr. Kjøller will be presenting at 11:00am PST on Monday, January 8, 2024, and will provide an update on the business with emphasis on key achievements and current status of the lead program orismilast, a potent selective PDE4 B/D inhibitor, currently in development

UNION therapeutics announces enrollment of the first patient in the UCORIS Phase 2 IIT study of orismilast in patients with ulcerative colitis

· UCORIS is an investigator-initiated, Phase 2 study of orismilast for the treatment of moderate to severe ulcerative colitis (UC) · UC is a chronic, inflammatory bowel disease with substantial unmet medical need for new oral treatments · Orismilast is a next-generation, high potency PDE4 B/D selective inhibitor with recently reported positive Phase 2b results in psoriasis and Phase 2 results in hidradenitis suppurativa (HS); orismilast also recently completed enrollment in an ongoing Phase 2b study in atopic dermatitis   Hellerup, Denmark, January 4, 2024 – UNION therapeutics A/

UNION therapeutics A/S announces new paper on clinical potential of the emerging class of PDE4B/D inhibitors published in journal of Dermatology and Therapy

· PDE4-inhibition is a well-established mechanism of action typically used for first line of treatment due to a well-documented safety and tolerability profile · As the understanding of PDE4 inhibition has evolved, PDE4B/D subtype inhibition has demonstrated to be critical in achieving anti-inflammatory effects, and selective PDE4B/D inhibitors may drive higher efficacy than previously approved PDE4 inhibitors   · UNION is developing orismilast, a safe oral, PDE4B/D inhibitor with broad anti-inflammatory properties   Hellerup, Denmark, November 29, 2023 – UNION therapeutics A/S (

UNION therapeutics A/S announces publication of results from the IASOS Phase 2b study of orismilast in psoriasis in Journal of the American Academy of Dermatology

· In the Phase 2b study, orismilast significantly reduced Psoriasis Area and Severity Index (PASI) compared with placebo from baseline to week 16 · 39.5% to 49.0% of patients treated with orismilast achieved PASI75 and 22.0% to 28.3% of patients achieved PASI90 · The clinical data supports the benefits of orismilast, a next-generation, high potency PDE4 B/D selective inhibitor · Orismilast is currently tested in an ongoing Phase 2b study in atopic dermatitis, and with recently reported positive topline Phase 2 results in hidradenitis suppurativa (HS)   Hellerup, Denmark,

UNION therapeutics A/S completes patient enrollment for ADESOS Phase 2b study of orismilast in patients with atopic dermatitis

· Topline results are expected in the first half of 2024 · Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the developed world and a significant unmet medical need exists for safe oral treatments · Orismilast is a next-generation, high potency PDE4 B/D selective inhibitor with recently reported positive Phase 2 results in psoriasis and hidradenitis suppurativa (HS)   Hellerup, Denmark, November 16, 2023 – UNION therapeutics A/S (UNION), a privately-held, clinical stage, pharmaceutical development company focused on immunology and infectious

UNION therapeutics to present at 7th Annual Dermatology Drug Development Summit in Boston

Hellerup, Denmark, October 25, 2023 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D. Kjøller, CEO of UNION therapeutics will present at the seminar on clinical trials at the 7th Annual Dermatology Drug Development Summit on October 31 - November 2, 2023, in Boston, US. Dr. Kjøller will discuss recent challenges and progress in assessing efficacy in clinical trials of hidradenitis suppurativa (HS) and how novel endpoints may improve the approach. To

UNION therapeutics announces presentation of new data on orismilast at the EADV Congress 2023

· Late-breaking presentation of data from the OSIRIS IIT PoC study of oral orismilast in hidradenitis suppurativa (HS) at the European Academy of Dermatology and Venerology Congress 2023 · Additional e-posters on the efficacy and safety of orismilast in moderate-to-severe psoriasis from the IASOS Phase 2b study and biomarker analyses from the skin of patients in the IASOS study, will be presented · Positive topline data from the IASOS study was reported early January 2023 and for the OSIRIS study in June 2023 · Orismilast is a next generation high-potency PDE4B/D selective

UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa

· Study demonstrates clinically relevant improvements in patients with hidradenitis suppurativa (HS) receiving 16 weeks of treatment with oral orismilast · Study supports the dose-finding results from the recent IASOS Phase 2b study of oral orismilast in psoriasis · Orismilast has been granted a Fast Track designation by the FDA for HS, and UNION plans to seek regulatory advice on the design of the pivotal study program · Orismilast is a high potency, next-generation PDE4 inhibitor with broad anti-inflammatory properties also in development for oral treatment of atopic dermatitis (

UNION therapeutics to present at 4th Annual Dermatology Drug Development Summit Europe

Hellerup, Denmark, May 10, 2023 – UNION therapeutics A/S (UNION), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D. Kjøller, CEO of UNION therapeutics will present at the seminar on hidradenitis suppurativa (HS) at the 4th Annual Dermatology Drug Development Summit Europe on May 22-24, 2023, in Berlin, Germany. Dr. Kjøller will discuss the current HS landscape incl. learnings on new ways to develop better treatments across dermatology and immunology.   Dr. Kjøller will also be

UNION therapeutics to participate at Kempen Life Science Conference

Hellerup, Denmark, April 21, 2023 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced participation at the Kempen Life Science Conference on April 25-26, 2023, in Amsterdam.   Contacts Morten Boesen, Chief Financial Officer, UNION therapeutics A/S +45 2381 5487 morten.boesen@uniontherapeutics.com   Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S +45 5385 3044 stj@uniontherapeutics.com   About UNION

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe